NovoCure Ltd NVCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
-
Novocure to Report Second Quarter 2026 Financial Results
-
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
-
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
-
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
-
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Trading Information
- Previous Close Price
- $16.03
- Day Range
- $16.03–16.53
- 52-Week Range
- $9.82–18.92
- Bid/Ask
- $16.42 / $17.00
- Shares Outstanding
- 115.82M
- Market Cap
- $1.90B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,605
- Website
- https://www.novocure.com
Valuation
|
Metric
|
NVCR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.61 |
Price/Sales | 2.67 |
Price/Cash Flow | — |
Price/Earnings
NVCR
Financial Strength
|
Metric
|
NVCR
|
|---|---|
Quick Ratio | 2.66 |
Current Ratio | 2.90 |
Interest Coverage | −11.91 |
Quick Ratio
NVCR
Profitability
|
Metric
|
NVCR
|
|---|---|
Return on Assets (Normalized) | −2.89% |
Return on Equity (Normalized) | −9.12% |
Return on Invested Capital (Normalized) | −2.05% |
Return on Assets
NVCR
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|M^?<@W | LOCK|Mtv%r | $155B | |||
| Stryker Corp
SYK
| LOCK|g$j&<&? | LOCK|?Rl | $121B | |||
| Medtronic PLC
MDT
| LOCK|Q^G%&# | LOCK|XDZf | $103B | |||
| Boston Scientific Corp
BSX
| LOCK|gS?LP^ | LOCK|!T@vz | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|rCDf<VH | LOCK|>NbHt | $50B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|ZMKh#< | LOCK|Z$w | $29B | |||
| DexCom Inc
DXCM
| LOCK|#p<JM>H | LOCK|Bgzkm | $28B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|t>B | LOCK|gD? | $26B | |||
| Steris PLC
STE
| LOCK|#pqgj> | LOCK|q<l&L | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|s?M$fdy | LOCK|n%f | $17B |
United States